Early chemotherapy in prostate cancer

Nature Clinical Practice Urology

Volumn 5, Issue 9, 2008, Pages 486-493

  Mazhar, Danish ^a   Waxman, Jonathan ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BICALUTAMIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ESTROGEN; ETOPOSIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; HORMONE; KETOCONAZOLE; LEUPRORELIN; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; STEROID; TAX 3501; UNCLASSIFIED DRUG; VINBLASTINE; WARFARIN;

ADJUVANT THERAPY; BLOOD TOXICITY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DRUG FATALITY; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 51549101993     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro1204     Document Type: Review

References (32)

1. Tannock IF et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764
2. Petrylak DP et al. (2004) Dooetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520
3. Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 1502-1512
4. D'Amico AV et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974
5. Carrol PR et al. (2001) Cancer of the prostate. In Cancer Principles and Practice of Oncology, edn 6, 1418-1476 (Eds DeVita VT et al.). Philadelphia, PA: Lippincott, Williams & Wilkins
6. D'Amico A et al. (2003) Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21: 2163-2172
7. D'Amico AV et al. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125-135
8. Eastham JA et al. (2002) Nomograms as predictive models. Semin Urol Oncol 20: 108-115
9. Pilepich MV et al. (2001) Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243-1252
10. Roach M 3rd et al. (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21: 1904-1911
11. Witjes WP et al. (1997) Preliminary results of a prospective randomized study comparing radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 NOMO prostatic carcinoma. Urology 49 (Suppl 3A): S65-S66
12. Schulman CC et al. (2000) 4-Year follow up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy. Eur Urol 38: 706-713
13. Van Popel H et al. (1995) Neoadjuvant hormone therapy before radical prostatectomy decrease the number of positivemargins in stage T2 prostate cancer: Interim results of a prospective randomized trial. J Urol 154: 429-434
14. Powell IJ et al. (2002) Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year follow-up, Phase II Southwest Oncology Group Study 9109. J Urol 168: 2016-2019
15. Pilepech MV et al. (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Protocol 85-31. J Clin Oncol 15: 1013-1021
16. Lawton CA et al. (2001) Updated results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49: 937-946
17. Klotz L et al. (2000) Neoadjuvant hormone therapy: The Canadian trials. Mol Urol 4: 233-238
18. Mazhar D et al. (2006) Improving outcomes in early prostate cancer: Part I - adjuvant treatment. BJU Int 98: 725-730
19. Pettaway CA et al. (2000) Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Onc 18: 1050-1057
20. Clark PE et al. (2001) Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57: 281-285
21. El-Rayes BF et al. (2002) Neo-adjuvant docetaxel and estramustine in patients with high risk/locally advanced prostate cancer [abstract #773]. In Proceedings of the American Society of Clinical Oncology: 2002 May 18-21; Orlando, FL
22. Oh WK et al. (2001) Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report. Semin Oncol 28 (Suppl 15): S40-S44
23. Garzotto M et al. (2002) Neoadjuvant weekly docetaxel and mitoxantrone in patients with high risk localized prostate cancer: A phase I trial [abstract #2434]. In Proceedings of the American Society of Clinical Oncology: 2002 May 18-21; Orlando, FL
24. Febbo PG et al. (2005) Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11: 5233-5240
25. Magi-Galluzzi C et al. (2007) Neoadjuvant docetaxel treatment for locally advanced prostate cancer: A clinicopathologic study. Cancer 110: 1248-1254
26. Gleave ME et al. (2004) Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer (CUOG-PO1a) [abstract 4635]. Proc Am Soc Clin Oncol 23 (Suppl): 414
27. Prayer-Galetti T et al. (2007) Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 100: 274-280
28. Konety BR et al. (2004) Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: Results of a phase I/II study. J Urol 171: 709-713
29. Zelefsky MJ et al. (2000) Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol 18: 1936-1941
30. Ben-Josef E et al. (2001) Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: Feasibility and preliminary results. Int J Radiat Oncol Biol Phys 49: 699-703
31. Schmidt JD et al. (1996) Evaluation of adjuvant estramustine phosphate, cyclophosphamide and observation only for node positive patients following radical prostatectomy and definitive irradiation. Prostate 28: 51-57
32. Wang J et al. (2000) Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. BJU Int 86: 675-680